- JP-listed companies
- ASKA Pharmaceutical Holdings CO., Ltd.
- Income statement
ASKA Pharmaceutical Holdings CO., Ltd. (4886) Income statement
Market cap
¥74.2B
P/E ratio
15.3x
Asuka Pharmaceutical Holdings operates through subsidiaries that manufacture prescription drugs, veterinary medicines, and medical devices for healthcare providers globally.
| 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | 56,607 | 60,461 | 62,843 | 64,139 | 71,127 |
| Revenue growth (%) | - | ||||
| Cost of revenue | 30,255 | 31,876 | 32,178 | 32,803 | 36,982 |
| Gross profit | 26,351 | 28,584 | 30,664 | 31,335 | 34,145 |
| Gross margin (%) | |||||
| Operating margin (%) | |||||
| Operating expenses | 21,556 | 23,476 | 24,164 | 26,003 | 28,311 |
| Operating income | 4,795 | 5,108 | 6,500 | 5,331 | 5,834 |
| Income before tax | 4,880 | 5,232 | 6,522 | 5,107 | 5,665 |
| Pretax margin (%) | 8.6 | 8.7 | 10.4 | 8 | 8 |
| Provision for income taxes | 1,873 | 1,118 | 2,316 | 1,091 | 1,366 |
| Effective tax rate (%) | |||||
| Net income | 4,290 | 4,238 | 7,545 | 5,101 | 5,625 |
| Earnings per share | 151.22 | 150.08 | 266.51 | 179.95 | 191.12 |
| Dividend per share | 15 | 16 | 40 | 55 | 60 |